CHRU De Nancy
Verified site
Vandoeuvre Les Nancy, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on patients with low‑risk, localized, non‑metastatic gastric adenocarcinoma that arises at the stomach or the junction where the stomach meets the esophagus. After surgery, the usual adjuvant approach is a combination of chemotherapy drugs given intravenous: docetaxel, oxaliplatin, fluorouracil together with calcium folinate, followed by the immune‑modulating agent durvalumab.
The purpose of the trial is to compare the standard post‑operative regimen with a de‑escalation strategy that uses only careful monitoring (surveillance) after surgery. Participants are randomly assigned to receive either the full chemotherapy and immunotherapy schedule, administered through a vein in a series of treatment cycles, or to enter the surveillance arm where no additional cancer‑directed drugs are given, but regular check‑ups are performed.
All participants will attend scheduled clinic visits for blood tests, imaging and physical examinations over a period of up to two years to assess whether the cancer returns and to record any side effects. The study collects this information to determine which approach provides the best balance of disease‑free survival and safety.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
13 criteria
9 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Vandoeuvre Les Nancy, France
Villejuif, France
Paris, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication given through a vein that helps the immune system recognize and attack cancer cells. In this study it is used after surgery as part of the standard treatment plan to try to keep the cancer from coming back.
is a vitamin‑like substance given by infusion into a vein. It is used together with chemotherapy to protect normal cells and reduce side effects, helping the chemotherapy work better.
is a chemotherapy drug given by injection into a vein. It works by stopping cancer cells from dividing and growing. In this trial it is part of the standard chemotherapy regimen given after surgery.
is another chemotherapy drug that is infused into a vein. It damages the DNA of cancer cells, which makes it harder for them to grow. It is included in the standard post‑operative chemotherapy schedule.
(often called 5‑FU) is a chemotherapy medication delivered by infusion. It interferes with the cancer cells’ ability to make DNA, slowing or stopping their growth. It is one of the drugs used in the standard chemotherapy regimen after surgery.
This medication is given as an intravenous infusion, typically 1500 mg per dose. It is an approved immune‑checkpoint inhibitor used in several cancers and is being studied for low‑risk gastroesophageal adenocarcinoma. It works by blocking the PD‑L1 protein, allowing the body’s immune cells to recognize and attack tumor cells. It belongs to the class of monoclonal antibodies that target PD‑L1.
Calcium folinate is administered by intravenous infusion at about 200 mg/m². It is a well‑known rescue agent used together with chemotherapy to lower side‑effects, especially with fluorouracil. The drug supplies a reduced form of folate that helps normal cells make DNA and protects them from damage. It is classified as a folate analog and a cytoprotective agent.
Docetaxel is given as an intravenous injection, usually 50 mg/m². It is a standard chemotherapy drug for many solid tumors and is part of the FLOT regimen for gastric cancer. The drug binds to tubulin proteins, preventing cancer cells from dividing properly. It is classified as a taxane, which is an antimitotic chemotherapy agent.
Oxaliplatin is delivered by intravenous infusion, typically 85 mg/m². It is a platinum‑based chemotherapy used in gastrointestinal cancers, including the FLOT protocol for gastric cancer. The drug creates cross‑links in DNA, stopping the tumor cells from copying their genetic material. It belongs to the class of platinum compounds, a type of alkylating‑like agent.
Fluorouracil is given as an intravenous infusion, commonly 2600 mg/m². It is a widely used chemotherapy for many cancers, such as gastroesophageal adenocarcinoma. The medication mimics the natural building block uracil and interferes with DNA synthesis, which hinders cancer cell growth. It is classified as an antimetabolite and a pyrimidine analog.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.